158 related articles for article (PubMed ID: 22135243)
1. The role of somatostatin and dopamine D2 receptors in endocrine tumors.
Gatto F; Hofland LJ
Endocr Relat Cancer; 2011 Dec; 18(6):R233-51. PubMed ID: 22135243
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Pituitary tumours: the sst/D2 receptors as molecular targets.
Hofland LJ; Feelders RA; de Herder WW; Lamberts SW
Mol Cell Endocrinol; 2010 Sep; 326(1-2):89-98. PubMed ID: 20438803
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
5. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
6. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
8. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
9. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
10. Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.
Boschetti M; Gatto F; Arvigo M; Esposito D; Rebora A; Talco M; Albertelli M; Nazzari E; Goglia U; Minuto F; Ferone D
Neuroendocrinology; 2010; 92 Suppl 1():17-22. PubMed ID: 20829613
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.
Arvigo M; Gatto F; Ruscica M; Ameri P; Dozio E; Albertelli M; Culler MD; Motta M; Minuto F; Magni P; Ferone D
J Endocrinol; 2010 Dec; 207(3):309-17. PubMed ID: 20876239
[TBL] [Abstract][Full Text] [Related]
12. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
Ren SG; Kim S; Taylor J; Dong J; Moreau JP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Nov; 88(11):5414-21. PubMed ID: 14602782
[TBL] [Abstract][Full Text] [Related]
13. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
Ferone D; Gatto F; Arvigo M; Resmini E; Boschetti M; Teti C; Esposito D; Minuto F
J Mol Endocrinol; 2009 May; 42(5):361-70. PubMed ID: 19141603
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
Ferone D; Arvigo M; Semino C; Jaquet P; Saveanu A; Taylor JE; Moreau JP; Culler MD; Albertelli M; Minuto F; Barreca A
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1044-50. PubMed ID: 16046458
[TBL] [Abstract][Full Text] [Related]
15. Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation.
Casnici C; Lattuada D; Crotta K; Mastrotto C; Franco P; Culler MD; Marelli O
J Neuroimmunol; 2006 Oct; 179(1-2):9-17. PubMed ID: 16904194
[TBL] [Abstract][Full Text] [Related]
16. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
17. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of new potential therapeutic applications of somatostatin analogs.
Pawlikowski M; Melen-Mucha G
Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
[TBL] [Abstract][Full Text] [Related]
20. New SRIF analogs in the control of human pituitary adenomas: perspectives.
Jaquet P; Saveanu A; Barlier A
J Endocrinol Invest; 2005; 28(5 Suppl):14-8. PubMed ID: 16114269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
